US Stock Insider Trading | TriSalus Life disclosed 6 insider transactions on February 23

K-LinePoet · 2026-02-24T00:07:42+00:00

TriSalus Life disclosed multiple insider transactions on February 23, 2026, including stock purchases by directors and executives, totaling $1,645,500. The company focuses on innovative drug delivery technologies and immunotherapy, aiming to improve treatment outcomes for liver cancer and pancreatic cancer.

K-LinePoet

2026-02-24 00:07:42

Abstract generation in progress

On February 23, 2026, TriSalus Life (TLSI) disclosed six insider trading transactions. Director Stansky Michael P purchased 243,900 shares.

[Recent Insider Transactions]

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
February 23, 2026	Director	Gordon Gary B., Stansky Michael P., Valle William	February 23, 2026	Buy	401,300	4.10	1,645,500
February 23, 2026	Director	Szela Mary T	February 23, 2026	Buy	30,500	4.10	125,000
February 23, 2026	Executive	Patience David	February 23, 2026	Buy	3,657	4.10	15,000
May 21, 2025	Executive	Cox Bryan F.	May 19, 2025	Buy	11,000	5.18	56,800
May 21, 2025	Executive	Marshak Richard	May 19, 2025	Buy	14,800	5.18	76,800
May 21, 2025	Executive	Devlin Jodi	May 19, 2025	Buy	19,400	5.18	100,300
May 21, 2025	Executive	Young James Emmett	May 19, 2025	Buy	13,200	5.18	68,200
May 21, 2025	Director	Murphy Sean	May 19, 2025	Buy	44,900	5.18	232,500
May 21, 2025	Executive	Stevens Jennifer	May 19, 2025	Buy	19,800	5.18	102,300
February 6, 2025	Executive	Young James Emmett	February 5, 2025	Buy	6,000	5.65	33,900

[Company Information]

TriSalus Life Sciences, Inc. is a Delaware corporation founded in 2009. They are engaged in the research, development, and sales of innovative drug delivery technologies and immuno-oncology therapies to improve treatment outcomes for difficult-to-treat liver and pancreatic cancers. Their technology is used to deliver treatments managed by interventional radiologists. They are developing and selling two product lines—currently used pressure drug delivery system (PEDD) and a research drug SD-101, which shows potential to enhance immune responses in treating hepatocellular carcinoma, pancreatic cancer, and other liver solid tumors. Their PEDD with SmartValve is the only technology that works in sync with the cardiac cycle, capable of opening collapsed vessels within tumors, enabling deeper perfusion and improved drug delivery under high tumor pressure. PEDD with SmartValve has been demonstrated in prospective and retrospective clinical studies and multiple preclinical models to improve treatment uptake and tumor response.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.